河北
分享至
来源：滚动播报
北京吉伦泰医药有限公司自主研发的1类创新治疗核药¹⁷⁷Lu-JLT003注射液（¹⁷⁷Lu-AB-3PRGD2）正式获得国家药品监督管理局药品审评中心（CDE）的临床试验批件。该药拟用于整合素αvβ3阳性的恶性肿瘤治疗。
特别声明：以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布，本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
